Prioritizing treatment experienced patients with hepatitis C infection for treatment with telaprevir: A number needed to treat approach

Hepatology

Volumn 55, Issue 5, 2012, Pages 1644-1645

  Rowe, Ian A ^a,b   Armstrong, Matthew J ^a,b   Houlihan, Diarmaid D ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TELAPREVIR;

CLINICAL DECISION MAKING; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HUMAN; LETTER; LIVER FIBROSIS; MORTALITY; OVERALL SURVIVAL; PATIENT COUNSELING; PRIORITY JOURNAL; RETREATMENT; RISK REDUCTION; TREATMENT OUTCOME; VIRUS RESISTANCE;

FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 84859935389     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25553     Document Type: Letter

References (4)

1. Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. HEPATOLOGY 2011; 54: 1538-1546.
2. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ 1999; 318: 1548-1551.
3. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-288, 288.e1.
4. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. HEPATOLOGY 2011; 53: 1742-1751.